Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the Company is discontinuing the Phase 2b PROPEL study of PTG-100 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Stifel Downgrades Protagonist Therapeutics (PTGX) to Hold Following Removal of PTG-100 From ModelMarch 26, 2018 1:49 PM Protagonist Therapeutics (PTGX) PT Lowered to $13 at BMO CapitalMarch 26, 2018 10:22 AM Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim AnalysisMarch 26, 2018 6:45 AM